Academic Journal
Q2Journal of Medical Economics
About Journal of Medical Economics
Journal of Medical Economics is a scholarly journal published by Taylor and Francis Ltd.. SCImago 2025 lists it in Q2, with an SJR of 0.843 and H-index of 61.
Coverage: 1998-2026. Research categories: Health Policy (Q2).
Source-backed journal facts
Topics in published research
Health Systems, Economic Evaluations, Quality of Life; Economic and Financial Impacts of Cancer; Medication Adherence and Compliance; Diabetes Treatment and Management; Atrial Fibrillation Management and Outcomes; Rheumatoid Arthritis Research and Therapies.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
Androgen receptor inhibitor double therapies in the management of metastatic castration-sensitive prostate cancer: a cost-effectiveness analysis
William V. Padula, Benjamin G. Cohen, Paul Steel, Sreevalsa Appukkuttan et al.
2026-12-31 · DOI: 10.1080/13696998.2026.2733865Cost-effectiveness of etranacogene dezaparvovec compared to eftrenonacog alfa for the treatment of adult patients with severe and moderately severe haemophilia B in Sweden
Songkai Yan, Olof Mogard, Anna Tjärnlund-Wolf, Fredrik Sjöö et al.
2026-12-31 · DOI: 10.1080/13696998.2026.2736995Real-world treatment patterns, healthcare resource utilization, and costs associated with high-risk endometrial cancer in England: a retrospective cohort study
Eleanor Ralphs, Vimalanand S. Prabhu, Erik Landfeldt, Jess Ridsdale-Smith et al.
2026-12-31 · DOI: 10.1080/13696998.2026.2738356Estimated cost, resource use, and health benefits of an increased use of next-generation multi-target stool DNA test for colorectal cancer screening from an integrated delivery network perspective
Michael Dore, Derek W. Ebner, A. Mark Fendrick, Chris Estes et al.
2026-12-31 · DOI: 10.1080/13696998.2026.2719374Cost-effectiveness of Orca-T vs allo-HCT with conventional GVHD prophylaxis for the treatment of advanced hematologic malignancies in the United States
Rawan Faramand, James Scott McClellan, Anna Pavlova, Rocio Manghani et al.
2026-12-31 · DOI: 10.1080/13696998.2026.2732644Assessing the consistency of overall survival extrapolations in Swedish health technology assessment reports of oncology treatments using extended follow-up data
Máté Szilcz, Olof Mogard, Mattias Ekman, Olof Lindgren et al.
2026-12-31 · DOI: 10.1080/13696998.2026.2736997Cost comparison of intravenous immunoglobulin and subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyneuropathy
Suraj A. Muley, Irene Gucciardi, Vivek Kaisare, Christoph Wissmann et al.
2026-12-31 · DOI: 10.1080/13696998.2026.2732441Incidence of comorbidities, healthcare resource utilization and costs among people with HIV
Joshua P. Cohen, Mary J. Christoph, Vamshi Ruthwik Anupindi, Nazneen Fatima Shaikh et al.
2026-12-31 · DOI: 10.1080/13696998.2026.2725506Clinical and economic value of onabotulinumtoxinA vs oral pharmacotherapies in overactive bladder in the United States
Doreen E. Chung, Benjamin M. Brucker, Stephen Chaplin, Qianyi Li et al.
2026-12-31 · DOI: 10.1080/13696998.2026.2732642Retrospective database analysis of annual direct costs and complications for patients with type 1 diabetes and hypoglycemia in the US
Adriana Boateng-Kuffour, Nanxin Li, Vamshi Ruthwik Anupindi, Keval Chandarana et al.
2026-12-31 · DOI: 10.1080/13696998.2026.2729739Cost-effectiveness analysis of pneumococcal vaccination of at-risk and high-risk adults aged 18–64 years in Switzerland using PCV21
Muloongo Simuzingili, Zinan Yi, Andrea Favre-Bulle, Thomas Mutschler et al.
2026-12-31 · DOI: 10.1080/13696998.2026.2726640Projected burden of bloodstream infections and the impact of molecular rapid diagnostic testing on costs and mortality in England and the United States (2025–2029): a population-level budget impact analysis
James K. Karichu, Mark Pennington, Kiera Lander, Tiffeny T. Smith et al.
2026-12-31 · DOI: 10.1080/13696998.2026.2728782Societal and fiscal gains from HPV vaccination in Poland – return on investment from extending access to HPV vaccination
Rafal Jaworski, Nikolaos Kotsopoulos, Marcin Czech, Mark P. Connolly et al.
2026-12-31 · DOI: 10.1080/13696998.2026.2728462Cost-effectiveness analysis of elranatamab versus physician’s choice of treatment (non–BCMA-directed regimens) in patients with triple class exposed multiple myeloma in Japan
Akira Yuasa, Mitsuhiro Nagano, Yoichi Kamei, Kengo Hatsuyama et al.
2026-12-31 · DOI: 10.1080/13696998.2026.2730069Real-world healthcare resource utilization and cost burden of COVID-19 in commercially insured adults at high-risk of severe disease in the US: a retrospective database analysis
Tendai Mugwagwa, Benjamin A. Abramoff, Siddharth Karanth, Tram Nham et al.
2026-12-31 · DOI: 10.1080/13696998.2026.2725478Cost-effectiveness analysis of Cardioform vs. Amplatzer: concerns regarding methodological transparency and interpretation of clinical results
David W. Hutton, Anne M. Ryschon, Scott Goates, Jan B. Pietzsch et al.
2026-12-31 · DOI: 10.1080/13696998.2026.2724710Budget impact analysis for albuterol–budesonide fixed-dose combination in the as needed treatment of adult patients with asthma in Kuwait
Gihan Hamdy Elsisi, Mohamed Al-Bader, Hanan Al-Razzuqi, Muneera Al-Asfoor et al.
2026-12-31 · DOI: 10.1080/13696998.2026.2725432Response to Hutton et al. letter to the editor
John J. Volpi, Lambertus F. Wolters, Timon Louwsma, Mitesh Nakum et al.
2026-12-31 · DOI: 10.1080/13696998.2026.2724713Costs and healthcare resource utilization after COVID-19 hospitalization among US Medicare patients: a retrospective claims analysis
Alon Yehoshua, Rachel M. Black, Anan Zhou, Michelle A. Silver et al.
2026-12-31 · DOI: 10.1080/13696998.2026.2722823Cost-effectiveness of nicotine metabolite ratio-guided smoking cessation therapy in China: a hybrid decision-analytic modeling study based on real-world data
Anqi Cheng, Min Wang, Yingman Gao, Tingfen Ji et al.
2026-12-31 · DOI: 10.1080/13696998.2026.2720308Reviews
Community Reviews
Version History
October 4, 2026 at 9:03 pm
October 2, 2026